Triaging suspected cancer with a multi-cancer early detection blood test
Menée en Angleterre et aux Pays de Galles à partir d'échantillons sanguins prélevés sur 5 461 patients présentant des symptômes non spécifiques ou potentiellement liés à un cancer gynécologique, pulmonaire ou gastro-intestinal (âge médian : 61,9 ans ; 66 % de femmes), cette étude multicentrique évalue la performance d'un test multicancer, basé sur la méthylation de l'ADN libre circulant, pour détecter précocement une néoplasie
Notable progress has been made in the field of circulating tumour DNA (ctDNA) analysis over the past decade. Along the spectrum of promising clinical applications of ctDNA across the various stages of cancer, blood-based genotyping in advanced cancer to guide targeted therapies, and more recently, molecular residual disease detection to improve patient selection for adjuvant therapy in stage II colon cancer, are the only indications with sufficient evidence to be integrated into routine clinical care. 1 , 2 Among the many other potential applications of ctDNA, a multi-cancer ctDNA test for early detection of multiple cancer types in otherwise healthy individuals, represents the most substantial opportunity to improve cancer survival.
The Lancet Oncology , commentaire, 2022